close

CombiMatrix Corporation, together with its subsidiaries, develops technologies, products, and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology, defense, and homeland security. Its technologies include a platform to produce user-defined, in-situ synthesized, and oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations, and proteins in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences, and nanotechnology. The company's products and services include CustomArray platform, an oligonucleotide array for genetic studies; CatalogArray Microarrays for gene expression studies, mutation analysis, and other studies; Micro-RNA Arrays that are used to study micro-RNA molecules; DNA Array Synthesizer, an instrument that enables researchers to fabricate DNA arrays to their specifications; stripping reagents, which enable researchers to re-use microarrays; ElectraSense Reader, an electrochemical scanning instrument; and comparative genomic hybridization arrays, which are used for research and molecular diagnostic applications. CombiMatrix Corporation also offers proprietary molecular synthesis and screening methods for the discovery of potential new drugs. In addition, the company develops capabilities of producing arrays that utilize bacterial artificial chromosomes that enable genetic analysis; and a series of compounds to address various oncology-related diseases. It sells its products and services directly, with partners, and through distributors to customers in the United States, Europe, and Asia. The company was founded in 1995 and is based in Mukilteo, Washington. CombiMatrix Corporation operates independently of Acacia Research Corp. as of August 16, 2007.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.70
Volume	1844
Volume Avg	7625
52 Week High	4.00
52 Week Low	1.33
PE	N/A
PE (group average)	57
EPS Year	-0.77
EPS change Q/Q	-30%
EPS change Q/Q Yr ago	1000%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-1000%
REV change Q/Q	12.5%
REV change Q/Q Yr ago	12.5%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%